Amneal Pharmaceuticals, Inc.
AMRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Amneal Pharmaceuticals, Inc. (AMRX) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $4.04B market cap, placing it firmly in the mid-cap category. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Market Cap
$4.04B
Beta
1.32
P/E (TTM)
34.19
P/E (Fwd)
11.02
EPS (TTM)
$0.37
EPS (Fwd)
$1.15
ROE
—
ROA
8.3%
Cash
$200.6M
Total Debt
$2.70B
Free CF
$101.5M
52W Change
75.4%
Annual Financials
Cash vs Debt
Amneal Pharmaceuticals, Inc. carries $2.70B in total debt against $200.6M in cash reserves — debt is roughly 13.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $101.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. An ROA of 8.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.21B (2022) to $3.02B (2025), reflecting a 36% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AMRX.